Recent Updates
Recently added Catalysts

Quetiapine Sustained Release

Phase 3

Major Depressive Disorder | Small molecule | Psychiatry |AstraZeneca PLC|Last Updated: Mar 25, 2009

Target and mechanism

ModalitySmall molecule

Also known as Quetiapine Fumarate Sustained Release

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment3,000

FDA Designations

No designations recorded

Clinical trial landscape

Quetiapine Sustained Release · 1 trial · 1 indication

Phase 3 1
NCT00278941Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive DisorderMajor Depressive Disorder
COMPLETED3,000 Analytics
PHASE3COMPLETED
Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive Disorder
Major Depressive Disorder
NCT002789413,000
Unlock trial analytics

Study Endpoints

Primary Endpoints

To evaluate the efficacy of quetiapine SR compared to placebo in increasing time from randomisation to a depressed event in patients with Major Depressive Disorder (MDD)

Secondary Endpoints

Evaluate quetiapine SR compared to placebo on health related quality of life.
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Interventions

NameTypeDescription
Quetiapine Fumarate Sustained ReleaseDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersNo
Study Sites168

Inclusion Criteria: * Documented clinical diagnosis according to the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision) meeting criteria 296.2x Major Depressive Disorder, * Single Episode, or 296.3x Major Depressive Disorder, Exclusion Criteria: * Patients ...

Countries:United StatesBulgariaCanadaPuerto RicoRomaniaRussiaSlovakiaUnited Kingdom
Unlock Eligibility Criteria

Competitive Landscape -Major Depressive Disorder 83 trials

Top 20 of 29 competitors

CompanyTickerTrialsLead PhaseDrugs
Neurocrine Biosciences, Inc.NBIX5PHASE3NBI-1065845
COMPASS Pathways Plc Sponsored ADRCMPS4PHASE3Psilocybin
AbbVie, Inc.ABBV2PHASE3Cariprazine
Johnson & JohnsonJNJ2PHASE3Esketamine, Midazolam
Axsome Therapeutics, Inc.AXSM2PHASE3Solriamfetol
Xenon Pharmaceuticals Inc.XENE3PHASE3Azetukalner
Definium Therapeutics, Inc.DFTX2PHASE3DT120
Eli Lilly and CompanyLLY1PHASE3Brenipatide
Takeda Pharmaceutical Co. Ltd. Sponsored ADRTAK1PHASE3Vortioxetine
Cybin, Inc.HELP3PHASE3CYB003
Vanda Pharmaceuticals Inc.VNDA1PHASE3Milsaperidone
Neumora Therapeutics, Inc.NMRA1PHASE3NMRA-335140
AtaiBeckley Inc.ATAI3PHASE2VLS-01-203 BU
Alto Neuroscience, Inc.ANRO1PHASE2ALTO-300
ACADIA Pharmaceuticals Inc.ACAD1PHASE2ACP-211
Supernus Pharmaceuticals, Inc.SUPN1PHASE2SPN-821
Seaport Therapeutics, Inc.SPTX2PHASE2SPT-300
Sunshine Biopharma IncorporatedSBFM1PHASE2Mitizodone
Masimo CorporationMASI1PHASE1Diprivan, Astra-Zeneca
Abbott LaboratoriesABT1N/AUndisclosed
Unlock Competitive Intelligence